Forte Biosciences Inc. has released its second quarter 2025 financial results. The company reported a net loss of $11.249 million for the quarter, compared to a net loss of $12.511 million for the same period in 2024. The comprehensive loss for the quarter was $11.249 million, showing a slight improvement from the $12.516 million loss reported in the same period last year. The company's general and administrative expenses decreased to $2.96 million for the quarter, down from $7.078 million in the same period of 2024, primarily due to reduced professional and legal expenses. Conversely, research and development expenses increased to $8.6 million, compared to $5.7 million in the previous year, driven by a $3.8 million rise in clinical expenses. Forte ended the quarter with $106.1 million in cash and cash equivalents. The company also completed a public offering in June, selling 5,630,450 shares of common stock and pre-funded warrants, raising net proceeds of $69.9 million. In July, the underwriters exercised their over-allotment option, resulting in additional net proceeds of $1.7 million. Forte continues to advance its FB102 program through clinical trials, with plans to present phase 1b data at the Tampere Celiac Disease Symposium in Finland in September 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814436081) on August 14, 2025, and is solely responsible for the information contained therein.
Comments